Identification of novel therapeutic options for venetoclax-resistant AML cells through drug repurposing

LADUNGOVÁ, Adriana, Daniel BUŠA, Yusuf LODHI, Jan HÝL, Martin ČULEN and Michal ŠMÍDA. Identification of novel therapeutic options for venetoclax-resistant AML cells through drug repurposing. In EHA 2022 in HemaSphere 2022; 6(S3): 626-627. 2022.

Basic information

• Original name: Identification of novel therapeutic options for venetoclax-resistant AML cells through drug repurposing
• Authors: LADUNGOVÁ, Adriana, Daniel BUŠA, Yusuf LODHI, Jan HÝL, Martin ČULEN and Michal ŠMÍDA.
• Edition: EHA 2022 in HemaSphere 2022; 6(S3): 626-627, 2022.

Other information

• Type of outcome: Conference abstract
• Confidentiality degree: is not subject to a state or trade secret
• Organization unit: Central European Institute of Technology

Links

• MUNI/A/1330/2021, interní kód MU: Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit IX (Acronym: VýDiTeHeMa IX)

Investor: Masaryk University

• MUNI/A/1419/2021, interní kód MU: Name: Specifický výzkum v oblasti „Life Sciences“

Investor: Masaryk University